Marker Therapeutics, Inc.’s common stock is listed on the Nasdaq Capital Market under the ticker symbol “MRKR”.
The company changed its name from TapImmune Inc. to Marker Therapeutics, Inc. on October 17, 2018.
The Company is headquartered in Houston, TX.
Marker Therapeutics is incorporated under the laws of the state of Delaware.
Marker’s fiscal year end is December 31.
The CUSIP number is 57055L 107.